AVROBIO, Inc. (AVRO)
11.15 -0.23 (-2.02%)
After hours: 6:39PM EST
Chart Events
Performance Outlook
| Previous Close | 11.45 |
| Open | 11.31 |
| Bid | 11.39 x 800 |
| Ask | 11.40 x 900 |
| Day's Range | 11.02 - 11.52 |
| 52 Week Range | 9.76 - 23.50 |
| Volume | 987,613 |
| Avg. Volume | 546,253 |
| Market Cap | 471.711M |
| Beta (5Y Monthly) | 1.40 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.31 |
| Earnings Date | Mar 15, 2021 - Mar 19, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 38.60 |
- Business Wire
AVROBIO Receives Orphan Drug Designation from the European Commission for AVR‑RD‑04, an Investigational Gene Therapy for Cystinosis
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the European Commission (EC) has granted orphan drug designation for AVR-RD-04, the company’s investigational gene therapy for the treatment of cystinosis. AVR-RD-04 consists of the patient’s own hematopoietic stem cells, genetically modified to express cystinosin, the protein that is deficient in patients with cystinosis. AVR-RD-04 is currently being evaluated in a Phase 1/2 clinical trial (NCT03897361) sponsored by AVROBIO’s academic collaborator at the University of California, San Diego.1
- Business Wire
AVROBIO to Present at Three Upcoming Investor Conferences in March
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that members of its senior management team are scheduled to participate in three upcoming virtual investor conferences.
- Benzinga
Avrobio Shares Rally On Fabry Disease Gene Therapy Encouraging Benefit In Early-Stage Study
Avrobio Inc (NASDAQ: AVRO) has reported positive data from the ongoing Phase 2 FAB-GTi Phase 1/2 trial evaluating AVR-RD-01, an ex vivo lentiviral gene therapy for Fabry disease. 100% reduction, or complete clearance, of the toxic substrate in the kidney biopsy, was observed in the first patient dosed. The company also announced six-month data from the first patient dosed in the Phase 1/2 trial of AVR-RD-02, an ex vivo lentiviral gene therapy for Gaucher disease type 1, showing substantial improvement over pre-gene therapy enzyme replacement therapy baseline in key biomarkers at six months post-gene therapy. Plasma chitotriosidase levels decreased 49%, and toxic metabolite lyso-Gb1 levels dropped 44% in the first patient at six months post-gene therapy, compared to the patient's pre-gene therapy ERT baseline levels. Additionally, preliminary data from the investigator-sponsored Phase 1/2 trial of AVR-RD-04 showed that all three cystinosis patients demonstrated strong data across multiple measures, including substantial improvement in photophobia in the first patient 12 months post-gene therapy. All patients remained off cysteamine pills, and eye drops, with trial enrollment completion expected this year. The Investor and analyst presentation is scheduled today at 8 a.m. ET. Price Action: AVRO jumped 19.6% at $20.46 in premarket trading on the last check Monday. See more from BenzingaClick here for options trades from BenzingaWell Health Scoops Up CRH Medical For Per Share; CRHM Shares SkyrocketNanoViricides' Broad-Spectrum Antiviral Drug Candidate Shows Encouraging Action In Preclinical Studies For COVID-19© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
